Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lifastuzumab Vedotin vs PLD in Platinum-Resistant Ovarian Cancer
NCT01991210Phase 2Terminated
- Sponsor
- Genentech
- Start
- Feb 2014
- Primary completion
- Aug 2016
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 7
01
Overview
A Phase 2 trial of lifastuzumab vedotin in ovarian cancer, primary peritoneal cancer (PPC), fallopian tube cancer (PFTC), sponsored by Genentech. Started Feb 2014; status: terminated.
02
Drugs
lifastuzumab vedotin
03
Conditions
ovarian cancerprimary peritoneal cancer (PPC)fallopian tube cancer (PFTC)
Beyond the preview
Go deeper on NCT01991210.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01991210.